XML 23 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net income attributable to Myriad Genetics, Inc. stockholders $ 131.1 $ 20.5 $ 117.2
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 54.4 48.3 26.8
Non-cash interest expense 0.2 0.4  
Gain on disposition of assets (0.2) (0.3) (0.9)
Share-based compensation expense 27.1 29.9 31.6
Impairment of cost basis investment   2.4  
Bad debt expense 32.3 37.3 33.3
Loss on extinguishment of debt   1.3  
Deferred income taxes (23.5) 0.8 13.2
Unrecognized tax benefits (0.3) 1.2 (2.4)
Change in fair value of contingent consideration (60.9) (0.8)  
Payment of contingent consideration (22.7)    
Changes in assets and liabilities:      
Prepaid expenses 3.3 7.8 (7.2)
Trade accounts receivable (39.2) (39.9) (25.9)
Other receivables 1.1 (4.0) (0.9)
Inventory 7.9 (1.2) (14.6)
Prepaid taxes   3.4 (3.7)
Accounts payable 4.0 (3.0)  
Accrued liabilities 1.4 1.2  
Deferred revenue (0.1) 0.9 (0.2)
Net cash provided by operating activities 115.9 106.2 166.3
CASH FLOWS FROM INVESTING ACTIVITIES      
Capital expenditures (8.4) (6.1) (5.0)
Acquisitions, net of cash acquired   (216.1) (37.0)
Sale of cost basis investment   2.6  
Purchases of marketable investment securities (80.9) (87.5) (164.5)
Proceeds from maturities and sales of marketable investment securities 77.7 160.8 115.1
Net cash used in investing activities (11.6) (146.3) (91.4)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Net proceeds from common stock issued under share-based compensation plans 36.9 6.0 94.3
Net proceeds from revolving credit facility 53.0 204.0  
Repayment of revolving credit facility (143.0) (105.0)  
Net proceeds from term loan   199.0  
Repayment of term loan   (200.0)  
Payment of contingent consideration recognized at acquisition (42.4)    
Fees paid for extinguishment of debt   (0.6)  
Repurchase and retirement of common stock   (31.6) (162.6)
Proceeds from non-controlling interest 0.5    
Net cash provided by (used in) financing activities (95.0) 71.8 (68.3)
Effect of foreign exchange rates on cash and cash equivalents (0.8) 2.2 (2.2)
Net increase in cash and cash equivalents 8.5 33.9 4.4
Cash and cash equivalents at beginning of year 102.4 68.5 64.1
Cash and cash equivalents at end of year $ 110.9 $ 102.4 $ 68.5